Implantica Gains Traction at AFS Meeting for RefluxStop U.S. Launch

The symposium, which drew over 120 experts, highlighted a shift in how medical professionals approach GERD. Unlike conventional surgical methods that encircle the esophagus—often leading to complications like dysphagia or an inability to belch—the RefluxStop procedure aims to restore natural anatomy without constriction. Dr. John Lipham, who moderated the panel, described the FDA approval as an inflection point for a condition that has seen little fundamental evolution in seven decades.

Industry interest proved significant enough that organizers had to turn away attendees from the over-booked session. Beyond the panel, Implantica executives held nearly 30 one-on-one meetings with specialists interested in adopting the device. With data indicating that over 40% of American patients continue to suffer from symptoms despite daily medication, the company is now moving to integrate the technology into clinical practice across major U.S. medical institutions.